167 related articles for article (PubMed ID: 36847415)
21. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature.
Suguro M; Tagawa H; Kagami Y; Okamoto M; Ohshima K; Shiku H; Morishima Y; Nakamura S; Seto M
Cancer Sci; 2006 Sep; 97(9):868-74. PubMed ID: 16856881
[TBL] [Abstract][Full Text] [Related]
22. [Screening of Differential Expression Autophagy Genes Related to the Prognosis of Diffuse Large B-Cell Lymphoma and Establishment of an Autophagy Model].
Zhang JD; Zhang HM; Lu D; Wang ZN; Chen HR; Lu XC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1101-1108. PubMed ID: 35981368
[TBL] [Abstract][Full Text] [Related]
23. Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study.
Chuang WY; Chang ST; Yuan CT; Chang GJ; Chang H; Yeh CJ; Ueng SH; Kao HW; Wang TH; Wan YL; Shih LY; Chuang SS; Hsueh C
Am J Surg Pathol; 2020 Feb; 44(2):232-240. PubMed ID: 31688139
[TBL] [Abstract][Full Text] [Related]
24. Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis.
Toyama K; Nakayama K; Terasaki S; Matsumura I; Kanaya S; Iino H; Noguchi H; Tahara K; Yoshida T; Saito A
J Clin Exp Hematop; 2023; 63(1):19-24. PubMed ID: 36990773
[TBL] [Abstract][Full Text] [Related]
25. Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.
Zhang YA; Yang X; Yao J; Ren Y; Liu P
Dis Markers; 2022; 2022():3276925. PubMed ID: 35774848
[TBL] [Abstract][Full Text] [Related]
26. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
27. A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma.
Zhang Z; Zhao C; Yang S; Lu W; Shi J
Lipids Health Dis; 2024 Jan; 23(1):20. PubMed ID: 38254162
[TBL] [Abstract][Full Text] [Related]
28. High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma.
Hou Y; Wang HQ; Ba Y
Med Oncol; 2012 Dec; 29(5):3498-503. PubMed ID: 22528513
[TBL] [Abstract][Full Text] [Related]
29. Development and Validation of a Novel Prognostic Nomogram for CD5-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Multicenter Study in China.
Shen Z; Wang L; Zhang B; Li T; Li D; He C; Xue Y; Wang Y; Li B; Liu Q; Zhang H; Gu W; Wang F; Wang C; Shi Y; Ye J; Zhu T; Miao Y; Huang S; Sang W
Front Oncol; 2021; 11():754180. PubMed ID: 34804942
[TBL] [Abstract][Full Text] [Related]
30. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.
Yoshioka T; Miura I; Kume M; Takahashi N; Okamoto M; Ichinohasama R; Yoshino T; Yamaguchi M; Hirokawa M; Sawada K; Nakamura S
Genes Chromosomes Cancer; 2005 Feb; 42(2):149-57. PubMed ID: 15543600
[TBL] [Abstract][Full Text] [Related]
31. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
Niitsu N; Okamoto M; Tamaru JI; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Hirano M
Ann Oncol; 2010 Oct; 21(10):2069-2074. PubMed ID: 20231297
[TBL] [Abstract][Full Text] [Related]
33. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.
Han Y; Yang J; Liu P; He X; Zhang C; Zhou S; Zhou L; Qin Y; Song Y; Sun Y; Shi Y
Oncologist; 2019 Nov; 24(11):e1251-e1261. PubMed ID: 30952824
[TBL] [Abstract][Full Text] [Related]
35. [CD5 expression is an adverse prognostic factor in diffuse large B-cell lymphoma].
Zheng Y; Ma XB; Jiang J; Wang YP
Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):156-60. PubMed ID: 22800477
[TBL] [Abstract][Full Text] [Related]
36. Pure intravascular recurrence of CD5-positive diffuse large B-cell lymphoma primarily arising from the nasal cavities.
Kano R; Masaie H; Hino A; Yasuoka H; Nagata S; Ishikawa J; Nakatsuka SI
Diagn Pathol; 2018 Jul; 13(1):46. PubMed ID: 30041681
[TBL] [Abstract][Full Text] [Related]
37. CCND2 mRNA Expression Is Correlated With R-CHOP Treatment Efficacy and Prognosis in Patients With ABC-DLBCL.
Wang D; Zhang Y; Che YQ
Front Oncol; 2020; 10():1180. PubMed ID: 32850340
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
39. De Novo CD5
Xu Y; Sun W; Li F
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e782-e790. PubMed ID: 32694049
[TBL] [Abstract][Full Text] [Related]
40. Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases.
Tagawa H; Tsuzuki S; Suzuki R; Karnan S; Ota A; Kameoka Y; Suguro M; Matsuo K; Yamaguchi M; Okamoto M; Morishima Y; Nakamura S; Seto M
Cancer Res; 2004 Sep; 64(17):5948-55. PubMed ID: 15342373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]